Piper Jaffray Raises PT On ABIOMED To $20

May 19, 2011 8:12 AM | 7 seconds read |

Piper Jaffray has raised the price target on ABIOMED ABMD from $15 to $20 and maintains its Overweight rating.

Posted In: Price Target Analyst Ratings Abiomed Health Care Health Care Equipment Piper Jaffray

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.